Lv6
2618 积分 2024-09-06 加入
Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial
25天前
已完结
RSV in 2025–26: immunisation gaps and opportunities
1个月前
已关闭
Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open‐label, multicenter study
2个月前
已完结
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
2个月前
已完结
Five-year population-based study of essential thrombocythemia in Taiwan: Epidemiology, treatment patterns, and sex-based disparities
2个月前
已完结
Long-term survival for myeloid neoplasms and national health expenditure: A EUROCARE-6 retrospective, population-based study
2个月前
已完结
Essential Thrombocythemia
2个月前
已完结
Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer
2个月前
已完结
Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis
3个月前
已完结
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer
3个月前
已完结
皖公网安备34019202002308
